Taken together, our findings suggest that the GB88 has therapeutic potential in exerting as an antagonist of PAR-2 expression as well as an anti-inflammatory drug, in the prevention of the allergy development triggered by mite protease allergens. This evidence concerns the gene F2RL1 and allergic disease.